Welcome to our dedicated page for Pharvaris news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris stock.
Pharvaris N.V. reports developments as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Its lead program, deucrictibant, is being developed in immediate-release capsule and extended-release tablet forms for on-demand and prophylactic treatment settings.
Recurring updates include clinical data from the RAPIDe and CHAPTER study programs, patient-reported outcome research, scientific publications, presentations at allergy and immunology meetings, financial results, strategic priorities, shareholder voting matters and capital-structure disclosures.
Pharvaris (Nasdaq: PHVS) reported first quarter 2026 results and a late-stage HAE pipeline update. Cash and cash equivalents were €247 million on March 31, 2026, excluding a subsequent $132.3 million underwritten offering that is expected to extend the cash runway into 2028.
Topline data from Phase 3 CHAPTER-3 of deucrictibant XR for prophylactic HAE treatment are expected in 3Q2026, and an NDA for deucrictibant IR for on-demand HAE treatment remains on track for 1H2026. Enrollment continues in the CHAPTER-4 extension and CREAATE Phase 3 AAE-C1INH study.
Pharvaris (Nasdaq: PHVS) closed an underwritten public offering of 4,455,863 ordinary shares, including full exercise of the underwriters’ option for 581,199 additional shares. Gross proceeds were approximately $132.3 million before fees and expenses. All shares were sold by Pharvaris under an effective SEC shelf registration.
Pharvaris (NASDAQ: PHVS) priced an underwritten offering of 3,874,664 ordinary shares at $29.68 per share, with gross proceeds expected to be approximately $115 million before underwriting discounts, commissions and expenses.
The underwriters have a 30-day option for an additional 581,199 shares. The offering is expected to close on or about May 11, 2026, subject to customary closing conditions.
Pharvaris (Nasdaq: PHVS) presented data at CIIC Spring 2026 showing that combined use of a 40 mg deucrictibant XR prophylactic tablet with one or two 20 mg IR capsules for breakthrough attacks is supported by calculated safety margins. A post-hoc CHAPTER-1 analysis showed comparable mean durations for icatibant-treated attacks across placebo and deucrictibant arms, offering initial evidence for the mechanism-on-mechanism approach. Pharvaris highlighted safety and early efficacy signals and said it will further explore combined prophylactic and on-demand deucrictibant use.
Pharvaris (Nasdaq: PHVS) reported Q4 and full-year 2025 results and provided a business update on deucrictibant clinical programs. Key milestones: CHAPTER-3 enrollment complete with topline data expected in 3Q2026, RAPIDe-3 pivotal success supports an on-track NDA submission in 1H2026, and cash of €292 million at year-end.
Company continues enrollment in CREAATE and long-term CHAPTER-4 extension while highlighting RAPIDe-3 median onset and resolution times versus placebo.
Pharvaris (Nasdaq: PHVS) announced publication of two Phase 2 trials in The Lancet Haematology showing deucrictibant, an oral bradykinin B2 receptor antagonist, had statistically significant efficacy and was well tolerated for both prophylaxis (CHAPTER-1) and on-demand treatment (RAPIDe-1) of hereditary angioedema (HAE) attacks.
The company said CHAPTER-1 showed reduced attack occurrence and improved quality of life, while RAPIDe-1 showed reduced attack severity and faster symptom relief; Phase 3 topline from CHAPTER-3 is expected in Q3 2026.
Pharvaris (Nasdaq: PHVS) published a peer-reviewed study validating patient-reported outcome (PRO) instruments for on-demand hereditary angioedema (HAE) treatment endpoints.
The non-interventional, mixed-methods study found PGI and AMRA tools reliable and sensitive, identified End of Progression™ as earliest meaningful endpoint, and aligned PGI-C "a little better" with AMRA-3 ≥20%, informing Phase 3 RAPIDe-3 endpoint hierarchy.
Pharvaris (Nasdaq: PHVS) presented Phase 3 RAPIDe-3 and Phase 2 CHAPTER-1 data at AAAAI 2026 supporting deucrictibant for on‑demand and prophylactic treatment of bradykinin‑mediated angioedema.
RAPIDe-3 met the primary and all 11 secondary endpoints: median onset of symptom relief 1.28 hours and complete resolution 11.95 hours versus much longer placebo times. CHAPTER-1 OLE showed mean attack rate fell from 2.18 to 0.12 attacks/month and roughly half of participants were attack free; no treatment‑related serious adverse events reported.
Pharvaris (Nasdaq: PHVS) will present six abstracts, including three Featured Posters, at the AAAAI 2026 Annual Meeting in Philadelphia from February 27–March 2, 2026. Key topics include pivotal Phase 3 RAPIDe-3 on-demand data, final CHAPTER-1 open-label results, and extended-release pharmacokinetics for CHAPTER-3.
Topline CHAPTER-3 results are anticipated in Q3 2026. Posters and slides will be posted on the company's investor site at the start of each presentation.
Pharvaris (NASDAQ: PHVS) outlined 2026 priorities focused on late‑stage development and regulatory filings for oral deucrictibant for bradykinin‑mediated angioedema. Key milestones: topline CHAPTER‑3 prophylaxis data expected 3Q2026; NDA preparation for on‑demand HAE treatment targeted for filing in 1H2026 based on RAPIDe‑3 and RAPIDe‑2; RAPIDe‑3 met its primary and all secondary endpoints with median onset of symptom relief of 1.28 hours (p<0.0001). CREAATE pivotal study in AAE‑C1INH is enrolling; CHAPTER‑4 long‑term extension is ongoing; CHAPTER‑1 open‑label data showed mean on‑treatment monthly attack rate of 0.12. Corporate runway is estimated into 1H2027, and Pharvaris was added to the Nasdaq Biotechnology Index in Dec 2025.